New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
Instead, they say the medications are most effective when used as part of a broader effort to improve long-term health
Manage Gastrointestinal Side Effects Communicate with Your Doctor : Discuss any persistent nausea, acid reflux, or vomiting with your prescribing physician
Genetic Factors and Individual Anxiety Susceptibility on GLP-1 Therapy Not everyone responds identically to GLP-1 medicationsgenetics play a significant role in how your body processes these drugs and how sensitive your mood pathways are to metabolic change
